

Subject Index

Adjuvant treatment, 70 (49), 71 (52), 74 (60), 75 (67), 77 (72), 108 (191)
 Early breast cancer, 70 (50)
 Endocrine therapy, 71 (51), 72 (55), 75 (66), 117 (215, 216), 119 (222, 224)
 Metastatic/advanced breast cancer, 68 (41)
 Pre-/perimenopausal patients, 71 (51)
 Radiotherapy, 64 (30), 112 (203)

Anastrozole – see under Aromatase inhibitors

Angiogenesis, 182 (435)
 Prognostic factor, 182 (435)

Apoptosis – see Tumour biology

Arimidex – see Aromatase inhibitors, anastrozole

Aromatase Inhibitors, 61 (23), 69 (46, 47), 71 (51), 72 (56), 75 (65), 130 (256), 138 (281), 140 (289, 290), 142 (297), 143 (300), 178 (421)
 Anastrozole, 61 (23), 69 (46, 47), 71 (51), 72 (56), 75 (65), 130 (256), 138 (281), 140 (289, 290), 142 (297), 143 (300), 178 (421)
 Exemestane, 71 (51), 126 (241), 162 (362)

Axillary lymph nodes, 84 (99), 128 (249), 162 (363)
 Micrometastasis, 84 (100)
 Prognostic factor, 83 (93), 84 (98), 85 (102), 171 (396), 181 (432)
 Ultrasonography, 92 (130)

Bcl-2, 180 (426)

Biopsy techniques, 16 (E7), 78 (74), 85 (101), 183 (438)
 Core needle, 90 (123), 91 (124), 97 (149), 168 (385)
 Needle localisation, 53 (4), 54 (5), 55 (6)
 Radioguided biopsy, 55 (6), 85 (104), 86 (105), 87 (111), 91 (124)
 Ultrasound guided, 47 (E22)
 Vacuum assisted biopsy, 88 (114), 94 (137), 98 (150)
 Wire-guided, 86 (105), 146 (313)

Bisphosphonates, 130 (255), 132 (263), 133 (265), 135 (272, 274), 136 (275), 138 (283)
 Ibandronate, 130 (255), 132 (263), 133 (265), 135 (272, 274), 136 (275), 138 (283)
 Pamidronate, 74 (61), 132 (261)
 Zoledronate, 74 (63), 77 (71), 107 (186), 127 (245, 246), 136 (277), 142 (296, 298)

Bone metastasis (see also Metastatic disease), 32 (E15)
 Bisphosphonates, 74 (61), 77 (71), 127 (245, 246), 130 (255), 133 (265), 135 (272, 274), 136 (275), 138 (283), 142 (296, 297, 298)
 Prevention, 74 (63)

Breast conserving surgery, 87 (110), 97 (146), 156 (341), 164 (368), 165 (373)
 Breast reconstruction, 139 (287), 166 (376)
 Early breast cancer, 157 (344), 163 (366, 367)
 Elderly/geriatric patients, 117 (214)
 Local recurrence, 121 (228), 139 (285), 161 (359), 163 (365)
 Neo-adjuvant chemotherapy, 122 (229), 157 (343)
 Radiotherapy, 157 (342), 166 (378)
 Residual tumour, 161 (359), 165 (372)
 Surgical practice, 94 (139), 120 (226), 165 (374)

Breast Units, 113 (209)

c-erbB-2 – see Her-2/neu

Chemotherapy/adjuvant chemotherapy, 2 (E1), 20 (E9), 72 (54), 74 (62), 137 (278), 182 (437)
 Alkylating agents, 77 (73), 128 (248), 131 (259), 141 (292), 143 (301), 146 (310), 175 (409)
 Antimetabolites, 76 (70), 134 (269, 270), 169 (387), 175 (409)
 Antineoplastic antibiotics, 137 (278), 143 (301), 145 (309)
 Anthracyclines, 128 (247, 248), 141 (294)
 Bisphosphonates, 127 (245, 246)
 Chemoradiotherapy, 65 (33), 148 (319)
 Chemosensitivity prediction, 159 (349), 170 (390)
 Doxorubicin, 77 (73), 129 (251), 132 (262), 141 (292), 148 (319)
 Early breast cancer, 66 (35)
 Epirubicin, 62 (24), 75 (64), 130 (257)
 5FU, 76 (70), 119 (224), 169 (387)
 Gemcitabine, 75 (64)
 High dose, 176 (413)
 High risk patients, 176 (413)
 Neoadjuvant chemotherapy, 18 (E8), 61 (21), 62 (24), 117 (216), 157 (343), 175 (409)
 Peri-operative chemotherapy, 62 (24, 25), 128 (247), 162 (363)
 Predictive factors, 172 (397)
 Taxanes, 62 (24), 75 (64), 129 (251), 137 (280), 146 (310), 162 (362)
 Toxicity and side effects, 71 (53), 76 (68), 77 (73), 140 (291), 141 (292, 294), 142 (295, 296, 297, 298), 143 (301, 302), 145 (307, 308, 309), 146 (310), 159 (351), 169 (387)
 Vinca alkaloids, 128 (247), 129 (252), 130 (254, 257), 131 (259), 134 (269, 270), 137 (279)

- Clinical practice/guidelines/attitudes**, 6 (E2), 99 (154), 117 (213)
 Clinical trials, 118 (218, 219), 125 (239), 126 (241), 128 (247), 139 (288), 161 (357, 360), 162 (363), 166 (378)
 Education, 28 (E13), 118 (221), 169 (387)
 General practice – education, 118 (220), 129 (252)
 Quality control, 91 (126), 113 (207), 124 (234, 235, 236)
- Clodronate – see Bisphosphonates**
- Complementary and alternative treatment**, 160 (355, 356), 161 (357, 358), 180 (429)
- Computers/simulation**, 77 (72)
- Cost control**, 72 (56), 75 (65, 67)
- Diagnosis**, 92 (128), 98 (151), 120 (225), 156 (339), 180 (427), 187 (455)
 Axillary lymph node involvement, 79 (79), 82 (89)
 Benign mammograms, 89 (118)
 Biochemical markers, 97 (147)
 Biopsy techniques, 78 (77), 79 (78), 87 (111), 183 (438)
 Cost-effectiveness, 171 (393)
 Delayed diagnosis, 89 (119), 96 (145)
 Ductal carcinoma in situ, 86 (106), 190 (466)
 Familial cancer, 96 (143), 103 (168)
 Metastasis, 67 (39), 128 (249)
 Nipple discharge, 95 (140), 98 (152), 136 (276)
 Pre-operative MR mammography, 87 (110)
 Recurrent disease, 93 (131), 95 (141), 96 (142), 126 (242)
 Self-examination, 87 (109)
- Diagnostic Imaging**, 57 (19), 81 (86), 92 (128), 120 (225)
 Cost-effectiveness, 94 (135)
 CT, 94 (136)
 Digital mammography, 34 (E16), 55 (9), 89 (120), 172 (397)
 Lymphoscintigraphy, 79 (78)
 Magnetic resonance, 86 (107), 87 (110), 91 (125, 127), 97 (146), 100 (159), 128 (249)
 Mammography, 56 (12, 13), 57 (18), 164 (371)
 Micro-endoscopy, 92 (129), 95 (140), 97 (148)
 PET, 95 (141), 126 (242)
 Ultrasonography, 40 (E19), 42 (E20), 45 (E21), 91 (127), 93 (132, 133), 94 (139), 96 (144)
- Docetaxel**, 125 (239)
 Adjuvant therapy, 71 (52)
 Metastatic/advanced disease, 131 (258), 133 (266)
- Drug resistance**, 170 (390)
- Ductal carcinoma in situ**, 14 (E6), 94 (137), 189 (462)
 Histopathology/classification, 80 (84), 84 (97), 86 (106), 121 (228), 175 (410), 190 (466)
 Local recurrence, 121 (228), 189 (461), 190 (465)
 Predictive factors, 84 (97), 190 (465)
 Prognostic factors, 188 (460), 189 (463), 190 (464, 467)
 Screening, 67 (38), 80 (84), 87 (112)
- Early breast cancer**, 65 (34), 66 (35), 182 (436)
 Adjuvant chemotherapy, 70 (50), 75 (65), 119 (223)
 Breast conserving surgery, 66 (36)
 Elderly/geriatric patients, 118 (218)
 Endocrine therapy, 75 (66), 84 (99)
 Radiotherapy, 150 (327)
 Second cancers, 74 (63)
- Elderly/geriatric patient care**, 69 (46, 47), 73 (57, 58), 117 (215), 118 (218), 183 (439), 189 (462)
 Outcome, 177 (417)
- Endocrine therapy/adjuvant endocrine therapy**, 12 (E5), 20 (E9), 61 (21), 126 (240)
 Early breast cancer, 66 (35)
 Faslodex, 73 (59), 132 (264, 264), 133 (267), 138 (281)
 Neoadjuvant therapy, 61 (23)
- EORTC trials**, 99 (155), 139 (286), 148 (318), 170 (392)
- Epidemiological studies**, 56 (12), 65 (34), 73 (58), 90 (121), 124 (235, 236), 151 (331), 176 (414), 183 (439), 184 (441, 442), 185 (447), 187 (456), 188 (457)
- Estrogen and progesterone receptors**, 132 (264)
- Exemestane – see under Aromatase inhibitors**
- Familial cancer/genetic testing**, 155 (336), 169 (387), 187 (454)
 BRCA1/BRCA2 carriers, 38 (E18), 53 (2), 65 (34), 96 (143), 100 (158), 112 (203), 150 (329), 151 (330, 331), 152 (332, 333, 334), 158 (348), 169 (389), 186 (451), 195 (469, 470)
 BRCA1/BRCA2 prevalence/screening, 53 (1, 3), 96 (143), 112 (203), 150 (329), 151 (331), 196 (473)
 Diagnosis, 186 (449)
 Genetic counselling, 184 (443), 186 (450), 195 (471)
 Mammography, 89 (117)
 Ovarian cancer, 103 (167, 168), 188 (458, 459), 196 (473)
 Psychological morbidity, 112 (203)
 Surveillance, 89 (117), 184 (443), 186 (450, 452)
- Her-2/neu**, 70 (48), 100 (157), 130 (256), 131 (258), 171 (394), 173 (403), 175 (407), 178 (421)
 ER positive tumours, 155 (337)
 FISH, 101 (162), 125 (239), 158 (346)
 HercepTest, 171 (393)
 Herceptin, 61 (22), 76 (69), 103 (167), 125 (239), 127 (243), 128 (250)
 Immunohistochemistry, 107 (183), 135 (273), 171 (395)
 P53, 61 (22)
 Predictive/prognostic factor, 138 (284), 157 (345), 158 (346, 347), 178 (419)
- Herceptin**, 101 (161), 173 (403)
 Blood brain barrier, 127 (244)
 Metastatic disease, 127 (243, 244), 128 (250), 132 (262), 137 (280)
 Toxicity and side effects, 145 (308)
 Vinorelbine, 130 (254)
- Hormone replacement therapy**, 112 (204), 123 (231)
 Complementary medicine, 112 (204), 123 (231)
 Risk factor, 57 (19), 123 (230), 155 (337)
- Letrozole – see under Aromatase inhibitors**
- Lymphoedema**, 146 (311), 169 (388)
 Adipose hypertrophy/liposuction, 168 (383)
 Breast conserving surgery, 144 (303)
 Collateral/substitution lymphatics, 147 (315)
 Manual lymphatic drainage, 146 (314)
 Prevalence, 144 (303)
 Ultrasound assessment, 168 (383)

Male breast cancer, 84 (98), 187 (453)

Metastatic/advanced breast cancer, 67 (38), 81 (86), 107 (187), 125 (237, 238), 129 (253), 138 (282), 177 (415), 181 (432)

Adjuvant chemotherapy, 68 (41)

Aromatase inhibitors, 130 (256), 143 (300), 178 (421)

Bisphosphonates, 130 (255), 132 (261, 263), 133 (265), 135 (274), 136 (275)

Bone marrow metastasis, 67 (39), 68 (41), 107 (186)

Bone (*see also* Bone metastasis), 32 (E15), 74 (61), 127 (245, 246), 130 (255), 132 (261, 263), 133 (265), 135 (272, 274), 136 (275, 277), 138 (283)

Docetaxel, 131 (258), 133 (266)

Endocrine therapy, 61 (23), 117 (216), 133 (267)

5FU, 131 (260), 135 (271)

Herceptin, 127 (243)

Meningitis, 134 (268)

Navelbine, 130 (257)

Vinorelbine, 131 (259, 260), 137 (279)

Nursing, 112 (205)

Paclitaxel, 62 (24), 75 (64)

Neoadjuvant therapy, 70 (48)

Pathology, 82 (89), 92 (128), 98 (153), 121 (228), 146 (312), 175 (410), 183 (438)

Techniques, 83 (96), 97 (148)

Predictive Factors, 8 (E3), 10 (E4), 173 (403), 181 (432)

Bcl-2, 178 (420), 180 (426)

BRCA1/p130Cas gene, 38 (E18), 100 (158), 151 (331), 152 (332, 334), 155 (335), 172 (398)

Estrogen receptor, 103 (169, 170), 155 (336, 337, 338), 173 (400), 179 (425)

Gene expression profiling, 158 (348)

Genetic markers – comparative genomic comparison, 159 (350), 195 (469)

Her-2/neu, 100 (160)

P53, 178 (420)

Progesterone receptor, 103 (169, 170), 155 (338), 177 (418)

Response to therapy, 158 (348), 159 (349)

Sentinel lymph node, 79 (80)

Prevention, 185 (445), 186 (449)

Chemoprevention, 184 (442)

Lifestyle factors, 185 (444), 186 (448, 451)

Prophylactic surgery, 156 (340)

Prognostic Factors, 8 (E3), 10 (E4), 22 (E10), 86 (108), 105 (176, 177), 172 (398, 399), 174 (405), 176 (414), 178 (422), 179 (423, 424), 180 (428), 182 (434), 183 (440), 184 (441), 185 (445)

Angiogenesis, 182 (435)

Axillary lymph node status, 81 (87), 174 (404)

EGFR, 104 (172)

Estrogen receptor, 179 (425)

Her-2/neu, 100 (160), 101 (162, 163), 103 (167), 106 (178), 157 (345), 158 (346), 171 (394), 174 (406), 175 (407), 178 (419)

Invasive lobular cancer – tumour grade, 190 (467)

MAGE-A gene expression, 105 (174)

New markers, 181 (433)

P53, 106 (178, 180), 174 (406), 175 (409), 178 (420)

Tumour size, 170 (391), 177 (415)

Urokinase-type plasminogen activator/inhibitor (uPA/PAI-1), 26 (E12), 76 (69), 173 (402), 175 (408), 180 (430)

VEGF, 100 (159), 104 (171)

Young age (<35 yrs), 163 (366), 169 (387), 185 (446)

Psycho-oncology, 159 (351), 183 (440)

Cost-effectiveness, 113 (207), 117 (216)

Counselling, 114 (210)

Education, 110 (196), 113 (206)

Family life, 67 (37), 69 (44), 112 (202)

Follow-up, 122 (229), 123 (232)

Mammographic screening, 55 (10)

Media influence, 157 (344)

Palliative care, 111 (201)

Patient/family communications, 69 (44), 110 (195, 196), 112 (202), 113 (208), 195 (472)

Patient survey, 110 (197), 111 (199), 114 (211)

Psychological morbidity, 68 (42), 69 (43), 109 (194), 110 (198), 111 (200, 201), 112 (204), 117 (214)

Psychosocial support, 69 (44), 111 (199, 201), 112 (205), 113 (206, 207, 208), 117 (213)

Public awareness, 114 (212)

Quality of life, 67 (37), 68 (42), 70 (50), 110 (198), 111 (200, 201), 160 (354, 356), 161 (358)

Risk explanation, 117 (213), 195 (472)

Radiotherapy/adjuvant radiotherapy, 36 (E17), 149 (325)

Axillary treatment, 148 (321)

Breast conserving therapy, 147 (316, 317), 148 (318), 149 (322), 157 (342), 161 (360)

Chemoradiotherapy, 65 (33), 148 (319)

Early breast cancer, 150 (327, 328)

Fractionated radiotherapy, 65 (32)

Intra-operative radiotherapy, 65 (31), 150 (326, 328)

Local/regional treatment, 64 (30), 65 (31), 121 (227)

Locally advanced disease, 148 (320)

Neoadjuvant radiotherapy, 64 (30)

Postoperative radiotherapy, 149 (323, 324), 160 (353)

Quality assurance, 160 (353), 161 (360)

Radiation-induced cancer, 169 (389), 175 (410)

Tissue toxicity, 121 (227), 146 (311)

Rare tumours, 177 (416)

Angiosarcoma, 144 (305)

Myoepithelial carcinoma, 176 (411, 412)

Screening, 53 (1), 55 (10, 8), 56 (12), 57 (15), 90 (121), 187 (454)

Adverse effects, 57 (14)

Cost effectiveness, 56 (11), 93 (134), 94 (135), 123 (233)

Early detection rate, 57 (16), 88 (113), 180 (428)

Efficiency, 87 (112), 88 (113), 89 (117, 119), 90 (122)

Elderly/geriatric patients, 187 (456)

Interval cancers – frequency, 86 (108), 90 (122)

Magnetic resonance imaging, 53 (3), 86 (107)

Mammography, 56 (13), 57 (16, 18), 173 (401)

Pathology – quality assurance, 57 (18)

Public awareness, 164 (371)

Quality assurance, 88 (116), 94 (138), 123 (233)

Recommendations, 55 (9), 56 (11), 93 (134), 191 (468)

Second screens, 86 (108)

Surveillance after mastectomy, 93 (131)

Ultrasonography, 53 (2)

Sentinel lymph node, 79 (80), 80 (84, 85), 81 (86), 82 (89), 83 (96), 84 (97, 98), 85 (102)

After previous biopsy, 78 (74)

Sentinel lymph node (*cont'd*)

Metastasis assessment, 68 (40), 79 (81), 80 (83), 190 (464)
 Predictive factors for involvement, 68 (40), 78 (75), 80 (82), 81 (87), 82 (91), 83 (94)
 Radioactive tracers, 78 (77), 82 (92)
 Radioguided surgery, 81 (88), 82 (90), 85 (104), 86 (106)
 Technique, 78 (77), 79 (79), 80 (83), 85 (101, 103)
 Validation study, 78 (76)

Signal transduction pathways – see Tumour biology**Supportive therapy**, 76 (68)

Surgery, 91 (126), 98 (153), 120 (226), 144 (305), 163 (366), 164 (370), 171 (396), 177 (416), 188 (459)
 Adjuvant chemotherapy, 162 (363)
 Ambulatory surgery, 110 (197), 164 (369)
 Anaesthesia, 168 (384)
 Breast reconstruction, 24 (E11), 139 (287), 166 (376), 167 (379, 380, 381, 382), 168 (384, 385), 169 (388)
 Breast Unit, 113 (209), 162 (364)
 Cancer recurrence, 163 (365)
 Complications, 144 (304, 306), 146 (311, 312)
 Follow up, 83 (95)
 Locally advanced cancer, 165 (375)
 Mastectomy, 66 (36), 139 (286, 288), 141 (293), 148 (320), 149 (323), 156 (340), 165 (373), 167 (379, 382), 168 (383, 386)
 Overview, 30 (E14), 159 (352)
 Pain relief, 141 (293)
 Prophylactic surgery, 167 (380)
 Quality assurance, 165 (374), 166 (377)
 Radioguided surgery, 161 (361)
 Technique, 139 (288)
 Tumour location, 88 (115)
 Ultrasound guided surgery, 88 (115)

Surgical margins – see Surgery**Tamoxifen therapy**, 109 (193), 161 (360)

Adjuvant tamoxifen, 70 (49), 72 (56), 75 (65, 66), 117 (215), 119 (222)
 Aromatase inhibitors, 140 (290)

Early breast cancer, 75 (66)
 Metastatic/advanced breast cancer, 126 (240, 241)
 Neoadjuvant therapy, 69 (46, 47), 73 (57), 174 (406)
 Post-menopausal patients, 140 (289)
 Toxicity and side effects, 140 (289), 143 (299)

Taxanes – see Docetaxel**Trastuzumab – see Herceptin**

Tumour biology, 2 (E1), 12 (E5), 100 (157), 105 (175), 181 (431), 182 (436, 437), 195 (469)
 Angiogenesis, 62 (26)
 Apoptosis, 62 (26), 63 (28), 109 (192), 186 (448)
 CYP17, 102 (164)
 Drug development, 63 (27, 28), 64 (29)
 Drug resistance, 61 (22), 106 (182)
 Estrogen receptors, 109 (192), 173 (400), 177 (418)
 Gene expression, 8 (E3), 10 (E4), 99 (155, 156), 101 (161, 162, 163), 102 (164), 104 (171), 105 (174), 106 (181), 107 (187), 108 (189, 190), 125 (237), 158 (348), 170 (390)
 Gene mutations, 169 (389)
 Growth factors and -receptors, 62 (26), 102 (165, 166), 104 (173), 155 (335)
 Matrix metalloproteinases (MMP), 170 (392)
 Mitosis, 107 (184), 108 (188, 191)
 P53, 106 (178), 107 (185)
 Proteomics, 159 (350)
 Signal transduction pathways, 62 (26)
 Sulta1A1, 102 (164)
 Tumour markers, 106 (179)
 Urokinase-type plasminogen activator/inhibitor (uPA/PAI-1), 26 (E12), 173 (402), 175 (408)
 VEGF, 104 (171)

Young patients, 66 (35, 36), 67 (37), 72 (54), 75 (66)**Zoledronate – see Bisphosphonates**